TransMedics Group
| General Information | |
| Business: |
We are a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. We developed the OCS to replace a decades-old standard of care that we believe is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide. Our innovative OCS technology replicates many aspects of the organ’s natural living and functioning environment outside of the human body. |
| Industry: | ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS |
| Employees: | 92 |
| Founded: | 1998 |
| Contact Information | |
| Address | 200 Minuteman Road. Andover, MA 01810, US |
| Phone Number | (978) 552-0900 |
| Web Address | http://www.transmedics.com |
| View Prospectus: | TransMedics Group |
| Financial Information | |
| Market Cap | $323.8mil |
| Revenues | $13.0 mil (last 12 months) |
| Net Income | $-23.8 mil (last 12 months) |
| IPO Profile | |
| Symbol | TMDX |
| Exchange | NASDAQ |
| Shares (millions): | 5.7 |
| Price range | $16.00 - $16.00 |
| Est. $ Volume | $91.0 mil |
| Manager / Joint Managers | Morgan Stanley/ J.P. Morgan |
| CO-Managers | Cowen and Company/ Canaccord Genuity |
| Expected To Trade: | 5/2/2019 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |